Zevra Therapeutics Income Statement (2014-2026) | ZVRA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	11.99M	1.97M	2.58M		1.25M	2.75M	2.02M	3.18M	8.47M	2.90M	12.92M	3.42M	4.40M	3.69M	12.01M	20.40M	25.88M	26.06M	34.17M	36.22M
Cost of Revenue (Quarter)	1.00M		0.06M	0.01M	0.02M	0.14M	0.09M	0.12M	0.68M	0.14M	1.23M	0.17M	3.57M	2.30M	1.37M	1.34M	12.38M	1.24M	1.52M	1.90M
Gross Profit (Quarter)	10.99M	1.97M	2.52M	-0.01M	1.23M	2.61M	1.93M	3.05M	7.79M	2.75M	11.69M	3.25M	0.83M	1.39M	10.65M	19.05M	13.50M	24.82M	32.65M	34.32M
Operating items
Amortization - Intangibles (Quarter)											0.77M	1.53M	1.55M	1.54M	1.62M	1.61M	1.62M	0.32M	0.32M	0.32M
Research & Development (Quarter)	2.85M	2.24M	2.81M	3.08M	4.79M	5.38M	19.80M	8.65M	7.43M	12.30M	11.42M	12.28M	10.52M	10.95M	8.35M	3.26M	3.43M	3.43M	2.62M	4.39M
Selling, General & Administrative (Quarter)	2.31M	1.95M	2.56M	2.73M	3.58M	0.05M	14.97M	7.23M	6.61M	5.82M	14.66M	9.93M	12.60M	16.21M	16.12M	19.55M	20.78M	16.93M	20.35M	20.78M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	1.00M		0.06M	0.01M	17.69M	4.07M	-23.44M										148.32M			43.31M
Operating Expenses (Quarter)	6.15M	4.19M	5.42M	5.82M	26.07M	9.50M	11.34M	15.88M	14.04M	18.11M	26.08M	22.21M	23.12M	27.15M	24.48M	22.80M	24.21M	20.37M	22.97M	25.18M
Operating Income (Quarter)	5.83M	-2.22M	-2.84M		-24.77M	-6.63M	-9.31M	-12.83M	-6.25M	-15.36M	-15.16M	-20.49M	-23.80M	-27.31M	-15.42M	-5.36M	-71.04M	4.14M	9.31M	52.15M
EBIT (Quarter)	5.83M	-2.22M	-2.84M		-24.77M	-6.63M	-9.31M	-12.83M	-6.25M	-15.36M	-15.16M	-20.49M	-23.80M	-27.31M	-15.42M	-5.36M	-71.04M	4.14M	9.31M	52.15M
Non-operating items
Interest & Investment Income (Quarter)	-0.01M	0.14M	0.12M	0.11M	0.75M	0.22M	1.03M	1.04M	1.55M	1.74M	0.21M	0.93M	0.27M	1.05M	-0.07M	0.54M	2.38M	2.31M	1.71M	3.59M
Other Non Operating Income (Quarter)	0.79M											-3.63M	1.79M	-6.74M	7.53M		135.35M	-6.56M	-265.91M	-7.20M
Non Operating Income (Quarter)	0.37M	0.46M	0.17M	12.35M	2.88M	-0.02M	6.11M	-0.49M	3.60M	5.17M	-4.74M	3.79M	3.94M	-5.92M	-4.95M	3.44M	147.94M	-5.12M	3.35M	-7.34M
Net income details
EBT (Quarter)	6.20M	-1.76M	-2.67M	10.48M	-21.93M	-5.70M	-3.01M	-13.32M	-2.65M	-10.19M	-19.89M	-16.69M	-19.86M	-33.23M	-20.37M	-1.92M	76.91M	-0.98M	12.67M	44.80M
Tax Provisions (Quarter)			0.03M	-0.00M	0.04M		-0.03M	-0.10M	-0.07M	0.18M		-0.07M	0.07M		15.37M	1.18M	2.20M	-0.43M	0.50M	6.91M
Profit After Tax (Quarter)	6.20M	-1.76M	-2.70M				5.75M	-13.22M	-2.57M	-25.90M	-6.80M	-16.62M	-19.93M	-33.23M	-35.74M	-3.10M	74.71M	-0.54M	12.16M	37.89M
Income from Continuing Operations (Quarter)	6.20M	-1.76M	-2.70M	10.49M	-21.97M	-5.70M	-2.97M	-13.22M	-2.57M	-10.37M	-19.89M	-16.62M	-19.93M	-33.23M	-35.74M	-3.10M	74.71M	-0.54M	12.16M	37.89M
Consolidated Net Income (Quarter)	6.20M	-1.76M	-2.70M	10.49M	-21.97M	-5.70M	-2.97M	-13.22M	-2.57M	-10.37M	-19.89M	-16.62M	-19.93M	-33.23M	-35.74M	-3.10M	74.71M	-0.54M	12.16M	37.89M
Income towards Parent Company (Quarter)	6.20M	-1.76M	-2.70M	10.49M	-21.97M	-5.70M	-2.97M	-13.22M	-2.57M	-10.37M	-19.89M	-16.62M	-19.93M	-33.23M	-35.74M	-3.10M	74.71M	-0.54M	12.16M	37.89M
Preferred Dividend Payments (Quarter)	16.90M
Net Income towards Common Stockholders (Quarter)	-10.70M	-1.76M	-2.70M	-1.86M	-24.04M	-6.62M	-9.02M	-11.77M	-2.57M	-10.37M	-19.89M	-16.62M	-19.93M	-33.23M	-35.74M	-3.10M	74.71M	-0.54M	12.16M	37.89M
Additional items
EPS (Basic) (Quarter)	-0.37	-0.05	-0.09	-0.05	-0.70	-0.19	-0.26	-0.34	-0.08	-0.30	-0.56	-0.40	-0.48	-0.69	-0.77	-0.06	1.36	-0.01	0.22	0.65
EPS (Diluted) (Quarter)	-0.37	-0.05	-0.09	-0.06	-0.81	-0.22	-0.30	-0.40	-0.09	-0.35	-0.67	-0.56	-0.48	-0.69	-0.77	-0.06	1.33	-0.01	0.21	0.63
Shares Outstanding (Quarter)	29.18M	35.22M	29.77M	34.51M	34.45M	34.49M	34.49M	34.47M	33.90M	34.73M	35.45M	41.78M	41.90M	47.81M	46.25M	54.10M	54.78M	55.95M	55.31M	58.41M
Shares Outstanding (Diluted) (Quarter)	29.18M	35.22M	29.77M	29.77M	29.77M	29.77M	29.77M	29.77M	29.77M	29.77M	29.77M	29.77M	41.90M	47.81M	46.25M	54.10M	56.33M	55.95M	57.26M	60.23M
Shares Outstanding (Entity) (Quarter)
EBITDA (Quarter)	5.83M	-2.22M	-2.84M		-24.77M	-6.63M	-9.31M	-12.83M	-6.25M	-15.36M	-15.16M	-20.49M	-23.80M	-27.31M	-15.42M	-5.36M	-71.04M	4.14M	9.31M	52.15M
Interest Expenses (Quarter)	2.07M	0.04M	0.01M	0.01M	1.75M	1.60M	0.36M	1.33M	0.20M	0.37M	-0.19M	6.20M	2.11M	6.50M	0.10M	5.83M	2.01M	2.05M	-2.93M	1.71M
Tax Rate (Quarter)			-1.27%	-0.04%	-0.17%		1.13%	0.77%	2.80%	-1.74%		0.42%	-0.35%		-75.47%	-61.66%	2.86%	44.32%	3.96%	15.43%

Research Tools

Developers

Zevra Therapeutics Income Statement (2014-2026) | ZVRA

Research Tools

Developers

Zevra Therapeutics Income Statement (2014-2026) | ZVRA

Create an account

Sign In

Reset Password